Screener
Eikon Therapeutics, Inc. EIKN Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Eikon Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216791
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Depreciation expense | 5,214 | 3,789 |
| Stock-based compensation expense | 2,777 | 2,970 |
| Amortization of operating lease right-of-use assets | (101) | 2,677 |
| Amortization of premiums and accretion of discounts on marketable securities | (827) | (1,234) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (4,377) | (2,686) |
| Other assets | 2,700 | (399) |
| Accounts payable | 5,324 | 2,277 |
Item 1. Condensed Financial Statements (Unaudited).
FAQ
- What is Eikon Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Eikon Therapeutics, Inc. (EIKN) reported accretion (amortization) of discounts and premiums, investments of $827K in Q1 2026.
Ask your AI about Eikon Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude